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Abstract
Medication errors are the second most common cause of adverse patient safety incidents and the single most 
common preventable cause of adverse events in medical practice. Given the high human fatalities and financial 
burden of medication errors for healthcare systems worldwide, reducing their occurrence is a global priority. 
Therefore, appropriate policies to reduce medication errors, using national data and valid statistics are required. 
The primary objective of this study was to provide a national ‘characteristic profile’ of medication error-associated 
adverse drug reactions (ADRs), which are also known as preventable ADRs (pADRs). A retrospective study of pADR 
reports submitted to the national pharmacovigilance center (PCV) within Iran’s Food and Drug Administration 
was conducted over a 2-year period (2015-2017). Preventability Method (P-Method), which is a standardized tool 
developed and recommended by the World Health Organization (WHO), was used for preventability assessment. 
The results of the analyses revealed that while the number of pADRs increased from year one to two (601 to 630), 
their proportion out of all ADRs per year decreased (7.32% to 6.44%). The percentage of pADRs was higher in 
females (61.01%) and adults (83.27%), and the highest number of reports were received by nurses (71.57%). Having 
‘a documented hypersensitivity to an administered drug or drug class’ was the most common preventable factor 
in both years (61.23% and 54.29% respectively), and ‘anti-infectives used systemically’ were the medication class 
which primarily contributed to both serious (53.29%) and non-serious pADRs (39.19%). The specific characteristics 
of medication errors associated with ADRs from this study, especially the preventable criteria which led to their 
occurrence, can help devise more specific preventative policies.
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Background 
Medication errors are defined as an “unintended failure in the 
treatment process that lead to, or have the potential to lead to, 
patient harm.”1 They are classified via different approaches, 
such as psychological mechanisms,2 their level of severity,3,4 or 
the processing stage in which they occur.5,6 Regardless of the 
system employed for their classification, “medication errors 
are the single most common preventable cause of adverse 
events in medical practice, and a major public-health burden 
with an estimated annual cost of US$42 billion, almost 1% 
of global expenditure on health.”7,8 One estimate by the US 
Institute of Medicine reported that medication errors cause 
1/131 outpatient and 1/854 inpatient deaths.9 Moreover, 
according to a report by the Iran’s Ministry of Health and 
Medical Education (MoHME), annual costs for prolonged 
hospitalization and extra care due to medication errors 
exceeded billions of Tomans (Iran’s currency).10 
Given the high human fatalities and financial cost of medication 
errors, the World Health Organization (WHO) launched its 
third Global Patient Safety Challenge – Medication Without 
Harm – in March 2017 and announced that one of its major 
goals is to reduce the level of severe, avoidable harm related to 
medications by 50% over 5 years, globally.11 
To date, a number of meta-analysis and review studies have 
been carried out on medication errors in Iran.12,13 However, 
the data from the individually reviewed studies had not used 
the same standardized definitions or detection methods for 
medication errors, or the focus was on its incidence within 
specific classes of drugs, healthcare professions or clinical 
settings. 
According to the guidelines for good pharmacovigilance 
practice by the European Medicines Agency (EMA), as 
well as the definitions and standards in the E2A guidelines 
of the International Conference on Harmonisation (ICH), 
an adverse drug reaction (ADR) is defined as “a response 
to a medicinal product which is noxious (harmful) and 
unintended when a causal relationship between a drug and 
an adverse occurrence is suspected. ADRs may arise from the 
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use of a product within or outside the terms of the marketing 
authorization, including off-label use, overdose, misuse, 
abuse and medication errors.”14,15 Furthermore, according 
to the National Coordinating Council for Medication Error 
Reporting and Prevention (NCC MERP), not all ADRs are 
caused by an error, however, the use of a drug as a result of an 
error is considered to be preventable.16 Therefore, medication 
errors associated with ADRs are also known as preventable 
ADRs (pADR). Since medication errors are a leading cause 
of pADRs, and national pharmacovigilance centers (PVCs) 
are considered to be a reliable source of ADR detection,17-19 
the evaluation of pADRs appeared to be a logical first step 
in characterizing a subset of medication errors in Iran which 
could in turn inform potential interventions to reduce their 
occurrence.20 
Since national statistics and comprehensive data regarding 
medication errors continue to be limited, this study aimed 
to develop a characteristic profile of medication errors using 
data from a regulatory body which are consistently collected, 
assessed and utilized in evidence-based policy making.
Methods 
Definitions
The definitions and explanations for the terms and variables 
in this study are provided below:
ADR – Any noxious and unintended response to a drug which 
occurs at doses normally used in humans for prophylaxis, 
diagnosis, or therapy of disease, or for the modifications 
of physiological function, where a causal relationship 
between the drug and an adverse event is suspected. The 
ICH guidelines note that ADRs may arise from the use of 
medications within or outside the marketing authorization 
terms, which includes off-label use, overdose, misuse, abuse, 
and medication errors.15 
pADR – A pADR is harm caused from drug use following a 
medication error, in which case the Preventability Method 
(P-Method) can be applied to determine the preventable 
criteria which led to its occurrence.16
Serious ADR – According to the ICH E2A criteria, serious 
ADRs are defined as reactions to a drug that result in death, 
permanent injury, significant disability/incapacity, or birth 
defect, and those requiring hospitalization or prolongation of 
existing hospitalization.15 
Medication classification – Medications were classified 
according to the WHO’s Anatomical Therapeutic Chemical 
(ATC) classification system, the active substances are divided 
into different groups according to the organ or system on 
which they act and their therapeutic, pharmacological 
and chemical properties. Drugs are classified in groups at 
five different levels. For the purposes of this study, data 
classification was analyzed at the first level which divides 
medicines in to 14 main groups.21 
Patient age groups – The age classification referenced in 
this study is that used by national health organizations to 
reimburse patients for medical expenses, which is also listed 
in the patient criteria for admission to pediatric (0–17 years 
old) and adult (≥18 years old) healthcare facilities.
Data Source/Data Collection
The data for this study was obtained through the national 
PVC within Iran’s Food and Drug Administration (FDA). 
The Iranian PVC became a full-member of the International 
Drug Monitoring Program of the WHO since 1998 and has 
been submitting ADR reports to the Uppsala Monitoring 
Centre since then. In 2013, the Moroccan PVC pioneered 
a multicenter study which evaluated the P-Method as an 
instrument for detecting and assessing pADRs, in which 
Iran was among a select number of participating countries.22 
In 2015, the Iranian PVC officially adopted P-Method to 
assess ADR preventability, and later incorporated certain 
modifications to this method, adjusting for national/domestic 
data. The PVC receives ADR reports documented in Yellow 
Cards (paper-based and online forms), which are standardized 
forms used to collect information about a suspected adverse 
event for further analysis. The form includes information 
pertaining to the patient, adverse event, suspected drug(s), 
seriousness and outcome of the event, actions taken, and the 
reporter. This information is communicated through several 
sources to the PVC: patients and their caregivers, trained ADR 
representatives in healthcare facilities (hospitals and clinics), 
as well as the Drug Poison Information Center (DPIC) which 
forwards suspected ADR incidents from the general public. 
In this retrospective study, the PVC server was used to extract 
pADR reports for a 2-year period since the implementation 
of P-Method (Year 1: March 2015–March 2016, and Year 2: 
March 2016–March 2017). 
Data Assessment
All assessment methods and processes carried out at the 
Iranian PVC follow the guidelines and recommendations of 
the WHO. ADR reports received by the PVC first undergo 
‘causality assessment’ using the WHO-UMC Causality 
Assessment System.23 This is a process used for establishing 
a causal relationship between a drug and an adverse event. 
Upon identification of an ADR, the next step is to decide 
whether it is preventable or non-preventable. pADRs can be 
assessed using P-Method; a validated tool that relies on explicit 
criteria for assessing preventability.22 This standardized tool 
aims to identify preventable risk factors (from 20 explicit 
criteria) that increase the probability of ADR occurrence in 
relation to three factors: healthcare professionals’ practices, 
patient behavior, and drug quality. The outcome of the 
preventability assessment using P-Method is one of the 
following: ‘preventable,’ ‘non-preventable,’ or ‘not assessable.’ 
The preventability criteria used in P-Method are presented in 
Table S1 (Supplementary file 1). If none of the preventability 
criteria are selected for an ADR, it is considered as ‘non-
preventable.’ Answering ‘yes’ to any of the criteria indicates 
that the ADR is ‘preventable’ and has a known risk factor. In 
year 1, the list included 20 preventable criteria as outlined in 
the original P-Method, however, in year 2, the Iranian PVC 
added ‘wrong drug’ as a new criterion to the list (number 9). 
The addition of this category was decided when certain ADRs 
were determined as preventable, but their preventable cause 
did not exactly match or could not fit in to any of the existing 
preventable categories.
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Data Verification
To rule out any systematic error or bias, and to take in 
to account for variability due to the subjective nature of 
applying P-Method, a random sample including 10% of 
all the pADR reports in each year was selected and re-
assessed for preventability by an independent evaluator 
at the FDA. This was done as part of an internal audit 
system to provide additional assurance of our data prior to 
being used by decision-makers at the FDA for developing 
national preventative policies. The primary application of 
P-Method was carried out by two experts at the PVC (NJN 
and MK). Photocopies of the original Yellow Cards (reports) 
for the randomly selected samples were prepared and the 
confidential patient information was redacted prior to being 
submitted to the FDA. Preventability assessment was repeated 
for each ADR by a clinical pharmacist at the FDA (ZFK), 
and the results were compared to determine the percentage 
of agreement between the reviewers. If the inter-reviewer 
agreement for the random pADR sample was >95%, it did not 
warrant further reassessment by additional experts. 
Statistical Analysis 
Descriptive statistics were used to summarize the rates of 
pADRs (frequency of pADRs among all reported ADRs 
in 2 years) by patient characteristics and event seriousness. 
The annual prevalence rates of pADRs were calculated and 
their preventable categories were reported for years 1 and 2. 
Further analysis was performed for the medication classes 
involved and reporters of the incidents (nurse, pharmacist, 
general practitioner, specialist, patient and other) over the 
two-year period. Since the preventability assessment tool 
(P-Method) was modified from year 1 to 2, the rates and 
preventable criteria for pADRs were reported separately for 
each year, but not compared statistically. All other factors 
such as patient characteristics, pADR seriousness, medication 
class, and the reporters of the incidents were reported for 
both years combined. Between groups, qualitative data were 
compared using 95% CI for rates reported. The analyses were 
performed using Microsoft Excel software (v15.0, 2013) and 
SPSS version 18.0 (IBM Corp., Armonk, NY, USA). 
Results 
Prevalence Rates 
From a total of 17 988 ADR reports received by the PVC over 
2 years, 1231 cases were identified as pADRs (6.84%) which 
were included in this study. In year 1, of a total of 8205 ADR 
reports, 601 (7.32%) were preventable, while in year 2, of 9783 
ADR cases, 630 (6.44%) were identified as preventable. 
Preventability
Data verification revealed a 98.4% inter-reviewer agreement in 
the preventability assessment of ADRs, which did not warrant 
further assessment by additional experts. The most frequent 
preventable risk factor leading to pADRs, in both years was 
‘having a documented hypersensitivity to an administered 
drug or drug class’ (61.23% and 54.29% respectively). The 
five most prevalent and least frequent preventable criteria 
for pADRs are compared in Table 1. Complete results are 
provided in Supplementary file 1.
The rates of pADRs in 2 years was stratified by gender, age, 
and seriousness which is presented in Table 2.
Medication Classification
The medication classes most commonly involved in pADRs 
over the 2-year period were systemic anti-infectives 53.29%, 
followed by nervous system 15.43%, antineoplastic and 
immunomodulating agents 8.94%, alimentary tract and 
metabolism 7.15%, and systemic hormonal preparations 
4.87%. In both years, anti-infective agents as well as 
antineoplastic and immunomodulating agents were the 
most common causes of serious pADRs, 39.19% and 29.73% 
respectively (Table 3).
Table 1. The 5 Most and Least Common Preventable Criteria for pADR Occurrence Compared Between Years 1 and 2
Preventability 
Criteria Year 1 (20 Criteria)
% pADRs/
All pADRs Year 2 (21 Criteria)
% pADRs/
All pADRs
Most prevalent 
1. Having a documented hypersensitivity to an 
administered drug or drug class
61.23% 1. Having a documented hypersensitivity to an 
administered drug or drug class 
54.29%
2. Inappropriate prescription for patient’s clinical condition 6.99% 2. Wrong drug 20.01%
3. Inappropriate prescription according to patient 
characteristics
5.16% 3. Drug administration error 6.67%
4. Drug administration error 4.66% 4. Poor quality drug administered 5.56%
5. Poor quality drug administered 3.83% 5. Wrong indication 3.65%
Least prevalent 
16. Withdrawal syndrome due to abrupt discontinuation 
of drug
0.83% 17. Necessary medication not given 0.32%
17. Expired drug administered 0.67% 18. Withdrawal syndrome due to abrupt 
discontinuation of drug
0.16%
18. Therapeutic duplication 0.63% 19. Expired drug administered <0.10%
19. Incorrect drug dosage formulation administered 0.48% 20. Incorrect laboratory or clinical monitoring of 
medicine 
<0.10%
20. Non-compliance 0.16% 21. Counterfeit drug administered <0.10%
Abbreviation: pADRs, preventable adverse drug reactions.
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Reporters
The majority of pADRs were reported by nurses 881 
(71.57%), while the least number of reports among healthcare 
professionals was submitted by medical specialists (3.74%). 
Only one report was received from a patient, and the 
remaining were communicated by ‘others’ 25 (2.03%), which 
includes caregivers or other groups of healthcare providers. 
This information is illustrated in Figure.
Discussion 
This is the first study to assess pADR data from the national 
PVC in Iran, using P-Method, since it was implemented in 
2015. 
The findings of this study showed that while the number 
of pADR cases increased from year one to two (601 to 
630), their proportion out of all ADRs decreased (7.40% to 
6.52%). This slight decline may reflect the impact of patient 
safety interventions by the MoHME. Nonetheless, there is 
continued need for work in this area. Furthermore, the rate 
of pADRs is generally reported to have a broad range, from 
18.7%–80%,22 which depends on multiple factors such as each 
country’s health culture, resources, and healthcare system, 
clinical setting and patient population being studied. One 
of the main advantages of P-Method in comparison to other 
preventability assessment tools is that it reports definitive 
pADRs instead of all possible, probable and definitive cases. 
This could also explain the lower rates of pADRs found in 
this study. That said, the rate of pADRs in Iran from this 
study seems to be comparable to those reported by other 
countries such as Sweden and Morocco24-26 which are among 
the Collaborating Centers for the WHO’s International Drug 
Monitoring Program27 and had used P-Method for reporting 
national pADR rates. 
Having ‘a documented hypersensitivity to an administered 
drug or drug class’ was the most common preventable 
factor leading to pADRs in both years. This is of particular 
interest since ‘anti-infectives used systemically’ were found 
to be the medication class that primarily contributed to the 
occurrence of both serious and non-serious pADRs. Given 
that antibiotics are among drug classes most commonly 
associated with hypersensitivity reactions and have a high per 
capita consumption in Iran,28 the importance of promoting 
the rational use of medicines and implementing more rigorous 
antimicrobial stewardship programs, in addition to ensuring 
comprehensive medication history and reconciliation could 
help prevent such ADRs. It should also be noted that this type 
of pADR could be a result of prescribing, dispensing and/
or administration errors. Therefore, developing appropriate 
preventative measures and educational programs in the 
above-mentioned areas should be among the priorities of all 
healthcare professional groups.
This study found that the rate of pADRs was higher in females 
compared to males. This was similar to a study conducted by 
the Moroccan PVC where the authors reported that from 
180 pADR cases over a period of 3 years, 53% occurred in 
women.18 The review by Aagaard and colleagues which 
assessed the global patterns of ADR over a decade (2000-
2009) similarly reported higher rates of ADRs in females 
(60%). The difference in pADR prevalence rates between the 
sexes could be due to multiple factors, such as difference in 
gender-associated healthcare-seeking behavior.29
Medication errors have been recognized as an area of 
concern in all age groups. As with other healthcare–related 
adverse events, patients at the extremes of age (pediatrics 
and geriatrics) are most vulnerable. Furthermore, due to 
inadequate clinical trials for medication use in pediatrics, 
children are at higher risk of developing unknown or rare 
ADRs. Nevertheless, this study showed that compared to 
adults, the rate of pADRs was considerably lower in pediatrics. 
This possibly reflects additional safety check in medication 
Table 2. The Prevalence Rates of pADRs by Gender, Age, and Seriousness
Patient and pADR 
Characteristics
Year 1 and 2
Proportion out of Total pADRs (% pADR)
Gender
Female 751/1231 (61.01%)
Male 480/1231 (38.99%)
Age
Pediatric (<18 y) 206/1231 (16.73%)
Adult (≥18 y) 1025/1231 (83.27%)
Seriousness
Serious 74/1231 (6.01%)
Non-serious 1157/1231 (93.99%)
Abbreviation: pADRs, preventable adverse drug reactions.
Table 3. Top 5 Medication Classes Most Commonly Involved in pADR Occurrence in 2 years
ATC Codes Top 5 Medication Classes Involved in pADR Occurrence
pADR/All ADRs
No. (%)
Serious pADR /All Serious ADRs
No. (%)
J01, J05–J06 Anti-infectives for systemic use 656 (53.29) 29 (39.19)
N01, N02 & N03 Nervous system 190 (15.43) 5 (6.76)
L01, L03–L04 Antineoplastic and immunomodulating agents 110 (8.94) 22 (29.73)
A01–A09 Alimentary tract and metabolism 88 (7.15) 0 (0.0)
H01–H02 Systemic hormone preparations 60 (4.87) 6 (8.11)
- Other medication classes 127 (10.32) 12 (16.22)
Total Reports (N) 1231 74
Abbreviation: pADRs, preventable adverse drug reactions; ATC, Anatomical Therapeutic Chemical.
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prescribing and administration by healthcare professionals 
in this particular patient population. The lower prevalence 
of chronic disorders and lighter medication burden among 
children, as well as their limited communication skills are 
other possible reasons. 
Apart from ‘anti-infectives used systemically,’ the results 
showed that similar to high-income countries, ‘antineoplastic 
agents’ were another major contributor to pADR occurrence.30 
The National Drug Policy (developed by the Iran FDA) 
aims to ensure availability, accessibility and affordability 
of medications, including those used for cancer treatment. 
Therefore, monitoring the impact of implementing national 
clinical guidelines will be beneficial for the safe use of these 
high-risk medication classes. 
The knowledge, attitude, and perception of various healthcare 
professionals regarding pharmacovigilance, as well as the 
reasons hindering their reporting of ADRs have been studied 
extensively.31,32 The percent of ADRs reported by different 
healthcare professionals varies among countries and practice 
settings. There are over 1140 trained ADR representatives in 
Iran, the majority of which include nurses and pharmacists 
(>95%). In this study, the largest portion of pADR reports 
were received from nurses (Figure). The surveys directed by 
the Iranian PVC following annual training sessions indicate 
that each professional group can better teach colleagues in 
their own profession, it would be important to train more 
physicians in pharmacovigilance so that they can support each 
other to recognize and report ADRs, while an interdisciplinary 
approach where pharmacists assist other clinicians would also 
be useful. 
Since its implementation in 2015, the application of P-Method 
in Iran has provided valuable insights. Analysis of pADRs in 
the first year demonstrated that certain pADRs could not be 
assigned to any of the existing preventability criteria. This 
resulted in the addition of a new criterion termed ‘wrong 
drug’ to the original P-Method list the following year. A 
retrospective sub-analysis of the pADRs assigned to this 
group revealed that the underlying preventable risk factors 
were primarily due to inadequate safety measures in the 
labelling and packaging of look-alike, sound-alike (LASA) 
drugs. In fact, the existence of confusing drug names has been 
determined as one of the most common causes of medication 
errors in Iran.33 Other risk factors leading to pADRs in this 
group included healthcare staff fatigue, physician’s illegible 
handwriting, and inappropriate work environment. Of note, 
the second most preventable criterion leading to pADRs in 
year two belonged to this newly added category. This may 
be due to this criterion encompassing a broader spectrum of 
risk factors, which did not require a more detailed analysis of 
each pADR report to determine whether it actually belonged 
to a more specific, existing category from the original list. 
To address this matter, a solution was proposed and recently 
adopted as policy by the FDA, which entailed further 
subdivision of this broad category into the more specific 
criteria noted above for future assessments of pADR. 
Limitations
The main limitation of this study is that since the preventability 
assessment tool (P-Method) was modified in the second year, 
the data could not be statistically compared between the two 
years to detect significant difference. Finally, since many 
ADRs could go unreported, the estimated pADR rate in this 
study is likely to be an underestimate of the true extent of 
ADR prevalence in Iran. 
Conclusion 
The results of this study demonstrated that similar to several 
other countries, anti-infective and antineoplastic agents are 
major contributors to pADR prevalence in Iran.
Given the differences in healthcare systems, certain preventable 
criteria are expected to be specific to each country’s setting. 
Therefore, it is recommended that each country consider 
these differences when adopting standardized assessment 
tools such as P-Method for preventability assessment. 
The specific preventable criteria predominantly causing 
pADRs revealed through this study will allow policy-makers 
to devise customized strategies for future prevention. 
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